New targeted drug BL-M07D1 enters early human testing for Hard-to-Treat cancers
NCT ID NCT05461768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that dose more closely. About 26 participants will be enrolled to check safety, side effects, and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (a drug given by IV infusion that targets HER2-positive cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced HER2-positive or low-expression breast cancer and other solid tumors who have run out of standard options.
What could go wrong
This is a very early Phase 1 trial with only 26 participants, so safety and dosing are still being figured out. It may not work or could have side effects, and it will take years before it might be available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan People's Hospital
RECRUITINGDongguan, Guangdong, China
Contact
Contact
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
Contact
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
Contact
Contact
Contact
-
Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangdong, Guangzhou, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
Zhongnan Hospital of Wuhan University
RECRUITINGWuhan, Hubei, China
Contact
Contact
Contact